Gilead Submits Biologics License Application to US Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living with Chronic Hepatitis Delta

Gilead Sciences, Inc. announced that it has submitted a Biologics License Application to the US FDA for bulevirtide for injection, a potential first-in-class antiviral medicine for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.